Emeryville, CA (PRWEB) July 10, 2012
The assets of Origen Therapeutics (http://www.origentherapeutics.com) innovative Antibody discovery and production platform are being immediately sold. Included in the sale is their extensive international patent portfolio, standard operating procedures, cell cultures and DNA stock, cultured avian (chicken) flock and lab equipment. Interested parties should express their interest by July 11, 2012.
About Origen Therapeutics
Origen Therapeutics has been focused on development and production of antibodies and enzymes. They have developed an avian transgenic platform for production of human sequence monoclonal and polyclonal antibodies and enzymes. Their platform provides next generation immunotherapeutics through discovery and production of novel antibody therapeutics derived from the company’s proprietary avian (chicken) transgenic technology. The focus of the company is the development of fully human sequence polyclonal antibodies for human therapeutic use, particularly to fight infectious disease and cancer. The technology platform can also be applied to the production of more effective and less expensive biopharmaceutical proteins, primarily enzymes.
+01 949 544 3355